Search

Displaying results 2661 - 2670 of 9670 in total
  1. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  2. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    [L2611] It is currently used as a pesticide, and not used in any FDA approved drug products. … [A32825] It may be combined with other ingredients, such as triclosan to serve as antifungal and antibacterial skin treatments.

  3. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  4. Drug

    Tilbroquinol

    go.drugbank.com/drugs/DB13222
    Approved

    Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467]. … In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis.

  5. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    It also inhibits prostaglandin biosynthesis.

  6. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    As it does not contain von Willebrand factor it is not indicated in von Willebrand’s disease [L41170]. … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as

  7. Drug

    Clascoterone

    go.drugbank.com/drugs/DB12499
    ApprovedInvestigational

    It binds to androgen receptors with high affinity. … [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766]

  8. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label]. … Eurartesim was first authorized for market by the European Medicines Agency in October 2011.

  9. Drug

    Smallpox (Vaccinia) Vaccine, Live

    go.drugbank.com/drugs/DB14711
    ApprovedInvestigational

    The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. … [L12747] In August 2024, ACAM2000 was additionally approved for the prevention of mpox infection in high-risk individuals.[L51499]

  10. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has made it a desirable target in the treatment these B-cell malignancies.